TOP > 外国特許検索 > COMPOSITION FOR TREATMENT AND DIAGNOSIS OF PANCREATIC CANCER

COMPOSITION FOR TREATMENT AND DIAGNOSIS OF PANCREATIC CANCER

外国特許コード F120006933
整理番号 S2011-0556
掲載日 2012年10月11日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2012JP057667
国際公開番号 WO 2012128377
国際出願日 平成24年3月16日(2012.3.16)
国際公開日 平成24年9月27日(2012.9.27)
優先権データ
  • 特願2011-061362 (2011.3.18) JP
発明の名称 (英語) COMPOSITION FOR TREATMENT AND DIAGNOSIS OF PANCREATIC CANCER
発明の概要(英語) The present invention relates to: a pharmaceutical composition for inhibiting the proliferation or metastasis of invasive pancreatic cancer in a subject, which comprises an anti-cancer molecular targeting drug and a pharmaceutically acceptable carrier, wherein the anti-cancer molecular targeting drug is produced by binding a toxin or a cytotoxic agent to an antibody capable of binding immunologically specifically to a cell surface folate receptor (FR) β protein of an FRβ (+) macrophage that exists around a pancreatic cancer cell at an invasive front; and a diagnostic agent and a kit, both of which can be used for determining the degree of malignancy of pancreatic cancer or the occurrence of invasive pancreatic cancer, and both of which are characterized in that it is determined that a cancer tissue is invasive and metastatic when a FRβ (+) macrophage is distributed around a pancreatic cancer cell at an invasive front.
従来技術、競合技術の概要(英語) BACKGROUND ART
Pancreatic cancer includes, early diagnosis is difficult and effective diagnosis method is not one of the cancer. Age of onset 40 years estimated pancreatic cancer By year -60, according to recent reports, the initial tumor cells until about 10 years to parental clone was required, then within one year and metastatic subclones of 5, further 1-2 other organs within one year and the transition to the estimated (non-patent document 1). And there is also a therapy, pancreatic cancer includes, difficult to cancer and the existing anti-cancer effect, surgical resection or radiation therapy is also performed, effective therapy has still not been established. About 80% stage IV of pancreatic cancer patients has been found and is in a state of terminal cancer, about 10% or less 5 - year survival rate is low. In addition, pancreatic cancer includes, on the mesenteric arteries, aorta, inferior vena cava such as infiltration of cancer into the large blood vessels, as well as, liver, metastasis to the lung organs such as easily causes, which, together with the level of difficulty in early diagnosis, contributing to the difficulty and the treatment. For example, inoperable pancreatic cancer chemotherapeutic to the patient survival rate is 50%, 4.4 in the case of 5-FU months, 5.7 months in the case of Gemcitabine has been reported (non-patent document 2). However, the location of the folic acid receptor β (FR β) infiltration of inflammatory macrophages is specifically expressed in cancer tissues and has been a report that, has been made by the present inventors (patent document 1, patent document 2, non-patent document 3 and non-patent document 4). The macrophages, referred to as tumor-associated macrophages, release angiogenic factors, and, to have properties inhibiting tumor immunity. Patent Document 1 is, an antibody which binds to FR β cell toxin or cytotoxic agent-conjugated complex as an active ingredient and a solid containing discloses a cancer therapy, as solid tumors, the tumor-associated macrophage accumulation, malignant glioma, breast cancer such as described in (Patent Document 1). Also, such as rheumatoid arthritis is an inflammatory disease of the FR β or associated with acute myelogenous leukemia are expressed at the cell surface, and, as a therapeutic agent of such diseases, and monoclonal antibodies and anti-cytotoxin conjugate FR β described (patent document 2, non-patent document 5 and non-patent document 6). Expression of FR β, peripheral blood monocytes and resident tissue macrophages are also known to be very small. (FR) is folic acid receptor, α, β, γ and δ and, in particular α is ovarian cancer, breast cancer, colorectal cancer, kidney cancer, lung cancers such as epithelial tumors exist on the surface of film, and between FR β FR α protein sequence identity can be about 70% as it is known (patent document 3 and patent document 4).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • TAKAO, Sonshin
  • MATSUYAMA, Takami
  • KURAHARA, Hiroshi
  • KUWAHATA, Taisaku
  • NAGAI, Taku
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close